We herein report on the application of phosphorodiamidate technology to both pyrimidine and purine nucleosides with anticancer activity to potentially overcome the resistance mechanisms associated with parent nucleosides. Sixteen symmetrical phosphorodiamidates prepared from natural amino acids such as L-alanine and glycine were synthesized. All the compounds were evaluated for their cytotoxic activity in a wide panel of solid and leukemic tumour cell lines. In addition, a carboxypeptidase Y assay was performed on a representative phosphorodiamidate in order to reveal the putative bioactivation pathway for the reported phosphorodiamidate-type prodrugs.
Introduction
Current chemotherapeutic treatment of cancer and viral infections is largely based on the use of antimetabolites, in particular modified nucleoside analogues (NA) mimicking natural purine or pyrimidine nucleosides. [1] In addition, there is also strong evidence that NAs have some potential as antibacterial agents. [2, 3] These molecules are often taken up by nucleoside transporters (NT) and then phosphorylated by specific nucleo(s)(t)ide kinases to the corresponding 5'-mono, di-and triphosphate forms. These metabolites interfere with de novo synthesis of DNA/RNA precursors leading to inhibition of DNA/RNA synthesis, with subsequent suppression of tumour cell growth or virus replication. However, NA activity is known to be limited by mechanisms associated with (i) poor cellular uptake (i.e. by a down-regulation in the expression of nucleoside transporters), (ii) poor conversion of the drug into an active metabolite (i.e.
by a down-regulation of nucleo(s)(t)ide kinases) or (iii) rapid degradation into toxic byproducts (i.e. by up-regulation of deactivating enzymes such as cytidine or cytidylate deaminases). [4, 5] Many prodrug strategies aim to overcome such resistance mechanisms associated with NAs to improve the NA's effectiveness. These include phosphate and phosphonate prodrug diesters pivaloyloxymethyl (POM), isopropyloxycarbonyloxymethyl (POC), cyclosaligenyl (cycloSal), S-acylthioalkyl (SATE), lipid and HepDirect and phosphoramidates in which an amino acid ester promoiety is linked via P-N bond to a nucleoside aryl phosphate. [6] [7] [8] This monophosphate prodrug approach, also called ProTide technology, is one of the most successful prodrug strategies, with an established position in the nucleotide prodrug area. This strategy, pioneered by Chris McGuigan's group, [9] led to the discovery and development of the clinically successful drugs sofosbuvir (Sovaldi) [10] and tenofovir alafenamide (TAF) [11] by Gilead Sciences. The first drug is approved for the treatment of chronic HCV infections, whereas the second to treat patients with either HIV or chronic HBV infections ( Figure 1 ). Other phosphoramidates are currently the subject of ongoing clinical trials as antiviral agents. Stampidine is in Phase I for the treatment of HIV infections [12] and GS-5734, more recently developed as a treatment for filovirus infections, [13] was moved forward through a Phase I clinical trial [14] as a consequence of the Ebola outbreak in West Africa in 2013-2016.
[15] GS-9131 is an orally bioavailable phosphonoamidate prodrug which has been shown to inhibit HIV-1 reverse transcriptase (RT) in multiple HIV-1 clinical subtypes and has a unique resistance profile toward N(t)RTI resistance mutations. GS-9131 is currently under clinical evaluation. [16] In the oncology arena, the first phosphoramidate to reach the clinic was thymectacin (NB1011) which was evaluated in a Phase I trial for the treatment of colon cancer. [17] Subsequently, our group designed and synthesised two phosphoramidate prodrugs named NUC-1031 [18] [19] [20] and NUC-3373 [21] [22] [23] (Figure 1 ). The gemcitabine phosphoramidate NUC-1031 is currently being evaluated in several clinical studies, including a Phase III study for patients with pancreatic cancer, a Phase II study for patients with ovarian cancer and a Phase Ib study for patients with biliary tract cancers.
The 5'-fluoro-2'-deoxyuridine (FUdR) ProTide NUC-3373 is currently being evaluated in a Phase I study for the treatment of a variety of solid tumours including colorectal and breast cancers. Although less extensively investigated than the ProTide approach, a second phosphoramidate strategy that has been reported by our group as a promising way for the delivery of nucleoside monophosphates inside the cell, is the phosphorodiamidate technology. [24] [25] [26] In this approach, two identical amino acid esters are introduced on the monophosphate moiety through a P-N bond in order to mask the negative charges. Due to their symmetric structure, phosphoro(no)amidates, where no phosphorus chirality arises, offer advantages over the aryloxy monoamidate analogues.
Although stereoisomers have the same chemical structure they may exhibit differences in their pharmacology, toxicology, pharmacokinetics and metabolism. For example, the Sp diastereoisomer of TAF is 10-fold more potent against HIV than the Rp diastereoisomer. [27] Likewise, in the HCV replicon assay, the Sp and Rp isomers of sofosbuvir demonstrated an approximately 18-fold difference in activity against HCV. [28] Though separation of the ProTide diastereoisomers by crystallization or by chromatography can be achieved in some cases, [29, 30] and different approaches to obtain ProTides in a diastereoselective [31] [32] [33] [34] and 5'-regioselective fashion [35] have been recently reported, in general most of these methodologies are not very efficient and are high-priced, time consuming and difficult to scale up. In this scenario the diamidate approach, if as effective as the ProTides in terms of activity, could be considered as a valid alternative, as demonstrated by 2'-C-methyl-6-O-methylguanosine-based phosphorodiamidate agents and their nanomolar anti-HCV activity in replicon assay. [24] Although the diamidate prodrug approach has been validated both in vitro and in vivo, to our knowledge, only one phosphonodiamidate, GS-9191 (Figure 1 ), has reached the clinic to date. GS-9191 is a nucleotide analogue under clinical evaluation as a topical ointment in patients with external genital and perianal warts caused by human papilloma virus infection. [36] Based on our preliminary findings, [24] [25] [26] considering the potential advantage of lack of chirality at the phosphorus atom for this class of prodrugs, and taking into account the extraordinary results obtained with gemcitabine and FUdR ProTides, we were interested to investigate the potential of the phosphorodiamidate approach when applied to these two nucleosides. We also took the opportunity to expand our study to other relevant anticancer NAs (1-7, Figure 2 ).
Herein, we report the synthesis, and biological activities of these target compounds (8-23) against a wide panel of cancer cell lines. Moreover, in order to support a putative bioactivation pathway for these prodrugs (in particular regarding the first activation step), we also report on carboxypeptidase Y assays for the gemcitabine phosphorodiamidate 8.
Figure 2.
Anticancer nucleosides considered for this study.
Results and discussion

Chemistry
The phosphorodiamidate prodrugs of gemcitabine (1), FUdR (2),
8-chloroadenosine (3), fludarabine (4), AraG (5), thioinosine (6-MP, 6), and thioguanosine (6-TG, 7), were prepared according to reported procedure. [37] This modified method, based on a Yoshikawa procedure to synthesize monophosphate species, [38] was successfully applied previously to a number of antiviral and anticancer nucleosides and led to identification of phosphorodiamidates, with L-alanine bearing either benzyl or 2,2-dimethoxypropyl as the most promising compounds. [24] [25] [26] Thus, in this work, we selected the above-mentioned amino acid esters as preferred entities and synthesized in total sixteen phosphorodiamidate prodrugs of seven anticancer NAs.
Moreover, for gemcitabine and FUdR, cyclohexyl, pentyl and cyclopentyl esters were also used, since these moieties afforded molecules with low submicromolar anticancer activity when applied in the ProTide approach. [18, 19] Additionally, for 8-chloroadenosine, another natural amino acid such as glycine was also included. In the This was also observed for AraG phosphorodiamidate 19. Thus, as already mentioned above, the significant reduction of potency of the prodrugs containing the neopentyl ester may indicate either poor cellular uptake and/or metabolic activation and/or higher susceptibility of L-Ala-Oneopentyl phosphorodiamidates as well as their metabolites to drug efflux pumps. [22] Generally, the maximal inhibition observed at the highest compound concentration (1λ8 M) for all tested compounds ranged between 7λ-100% except for 19, the diamidate of AraG (22% in CCRF-CEM and 25% in MOLT-4). 
a IC50 or compound concentration required to inhibit tumour cell proliferation by 50%.
Data are the mean (SD) of at least two to four independent experiments.
Enzymatic Studies
The general putative mechanism of the bioactivation pathway for phosphorodiamidates is depicted in Scheme 2 and is similar to the metabolic route postulated for the phosphoramidates [39, 40] Finally, the formation of the metabolite 8-C lacking one of the amino acid (thought to be mediated by spontaneous cyclisation and hydrolysis) (8-B) was confirmed by the presence of the single peak at δp 7.04 ppm. This is analogous to results reported in our previous study. [24] No direct The same activation pathway with a similar estimated half-life was obtained with inactive compound 18, the phosphorodiamidate of AraG (data not shown). These results indicate that discrimination between active and inactive compounds might be ascribed to the last step in the activation pathway, catalysed by Hint, a phosphoramidase type enzyme. [41] [42] [43] Figure 3. Carboxypeptidase Y-mediated cleavage of compound 8 as monitored by 31 P NMR.
Conclusion
In conclusion, we report on the application of the phosphorodiamidate approach leading to sixteen prodrugs derived from amino acids and seven anticancer nucleoside The combined organic layers were dried over Na2SO4 and concentrated. The residue was purified unless otherwise stated either by column chromatography or Biotage Isolera One to give the title compound as a white solid.
2'-Deoxy-2',2'-difluoro-D-cytidine-5'-O-bis(benzoxy-L-alaninyl)] phosphate (8):
Prepared according to the standard procedure A from gemcitabine (0.25 g, 0.95 mmol), POCl3 (0.29 g, 0.17 mL, 1.89 mmol), followed by addition of L-Ala benzyl ester tosylate salt (1.67 g, 4.75 mmol), DIPEA (1.23 g, 1.65 mL, 9.50 mmol). Column purification followed by preparative TLC purification gave the product 8, as a white solid (0.079 g, 12%). 31 from 100/0 to 0/100 in 35 min, F = 1 mL/min, = 254, tR = 17.72 min. 
5-Fluoro-2′-deoxyuridine-5′-O-bis(2,2-dimethylpropoxy-L-alaninyl) phosphate
